NetraMark Holdings (FRA:PF0) Valuation Rank


FRA:PF0 NetraMark Holdings Inc FRA:PF0
27 GF Score
Price €0.43
GF Value €0.19
! 2 Warning Signs
View Full Analysis

What is NetraMark Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NetraMark Holdings Valuation Rank Related Terms

FRA:PF0
27GF Score
NetraMark Holdings Inc FRA:PF0
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NetraMark Holdings (FRA:PF0) Overvalued in 2026?

Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued. The current stock price of €0.43 is trading 127.4% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:PF0:

  • Valuation Rank:
  • GF Value™: €0.19 vs. price of €0.43 (127.4% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the FRA:PF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NetraMark Holdings Business Description

Address 1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
27GF Score

Get the complete analysis for FRA:PF0

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.43
Price
€0.19
GF Value